Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
ASCO Highlights
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
ASCO Highlights
,
Biliary Tract Cancer
,
Cholangiocarcinoma
,
Pancreatic Cancer
March 2021, Vol 2, No 1
— April 13, 2021
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
Read More
Final Results from ClarIDHy: Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation
ASCO Highlights
March 2021, Vol 2, No 1
— April 13, 2021
Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (IDH1) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and IDH1 mutation. Although this improvement did not reach statistical significance, after adjusting for crossovers from the placebo to the ivosidenib group, the difference in median OS was statistically significant.
Read More
Key Cholangiocarcinoma Abstracts Presented at ASCO GI 2021
By
Rachna T. Shroff, MD, MS
ASCO Highlights
Videos
— January 20, 2021
Rachna Shroff, MD, from the University of Arizona Cancer Center, presents her insights into important new data in cholangiocarcinoma from ASCO GI 2021. New evidence is being presented on FGFR inhibitors, targeted therapies, chemotherapy in second-line, combination therapy, immunotherapy, and more.
Read More
Comparing Primary Tumor, Metastatic Tumor Tissue, and Liquid Biopsy in Intrahepatic Cholangiocarcinoma: Comprehensive Genomic Profiling Study
ASCO Highlights
August 2020, Vol 1, No 1
— September 10, 2020
Genomic alterations that are characteristic of intrahepatic cholangiocarcinoma (CCA) are well known. A study led by Jeffrey S. Ross, MD, Medical Director, Foundation Medicine, Cambridge, MA, examined whether genomic alterations from a primary tumor would differ from metastatic tumor tissue and liquid biopsy in patients with intrahepatic CCA. The study results were presented at the 2020 ASCO annual meeting.
Read More
Adjuvant Concurrent Chemoradiotherapy in Extrahepatic Cholangiocarcinoma
ASCO Highlights
August 2020, Vol 1, No 1
— September 10, 2020
Treatment with 6 months of adjuvant capecitabine chemotherapy is currently the standard of care in patients with resected extrahepatic cholangiocarcinoma (CCA). However, the benefit of treatment with adjuvant radiation therapy is not well-defined.
Read More
ClarIDHy Phase 3 Study: IDH1 Mutation Detection in ctDNA and Clinical Response in Patients with Advanced Intrahepatic Cholangiocarcinoma
ASCO Highlights
August 2020, Vol 1, No 1
— September 10, 2020
Mutations in
IDH1
are detected in approximately 13% of patients with intrahepatic cholangiocarcinoma (CCA). ClarIDHy was a global, phase 3, double-blind clinical trial in previously treated patients with advanced intrahepatic CCA with
IDH1
mutation.
Read More
Phase 2 Study of Modified FOLFOX versus Modified FOLFIRI in Patients with Locally Advanced or Metastatic Biliary Tract Cancer Refractory to First-Line Chemotherapy
ASCO Highlights
August 2020, Vol 1, No 1
— September 10, 2020
In patients with locally advanced or metastatic biliary tract cancer, treatment with second-line chemotherapy is challenging after disease progression from first-line gemcitabine plus cisplatin, although treatment with modified FOLFOX (mFOLFOX) has been proven to be superior to active symptom control in the ABC-06 trial. Irinotecan (Camptosar) is an active drug used in the treatment of various gastrointestinal cancers.
Read More
TreeTopp: Phase 2 Study of Varlitinib plus Capecitabine versus Placebo as Second-Line Therapy for Patients with Advanced or Metastatic Biliary Tract Cancer
ASCO Highlights
August 2020, Vol 1, No 1
— September 10, 2020
Varlitinib is a reversible small-molecule, pan human epidermal growth factor receptor (HER) inhibitor with low nanomolar potency against HER1 (EGFR), HER2, and HER4.
Read More
FOENIX-CCA2: Phase 2 Open-Label Study of Futibatinib in Patients with Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions
ASCO Highlights
August 2020, Vol 1, No 1
— September 10, 2020
Futibatinib is a highly selective irreversible fibroblast growth factor receptor (FGFR)1-4 inhibitor, administered as a continuous once-daily oral regimen. The FOENIX-CCA2 phase 2 clinical trial was initiated after the results from a phase 1 dose-escalation/expansion study showed the tolerability and preliminary efficacy of futibatinib in patients with intrahepatic cholangiocarcinoma (CCA) and
FGFR2
fusions.
Read More
Natural History of Cholangiocarcinoma with FGFR Alterations
ASCO Highlights
August 2020, Vol 1, No 1
— September 10, 2020
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are emerging as promising therapeutic targets in patients with cholangiocarcinoma (CCA). A retrospective chart review, led by Lipika Goyal, MD, MPhil, Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, was performed in patients with CCA who had an
FGFR
alteration found by tumor molecular profiling as part of routine care.
1
Dr Goyal presented this study at the 2020 ASCO annual meeting.
Read More
Page 3 of 4
1
2
3
4
View the Latest Issue of CCA News
Read Issue
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
CCA News
Print Edition
CCA News
Weekly e‑Newsletter
-- Please Select Country --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
CCA News
's
Privacy Policy
, and
CCA News
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION